Here’s what diabetes tech companies are doing for National Diabetes Awareness Month

As we enter November, we enter National Diabetes Awareness Month. A number of diabetes technology developers plan to mark that in a special way.

Dexcom (Nasdaq:DXCM), Insulet (Nasdaq:PODD) and Embecta (Nasdaq:EMBC) all announced their plans to celebrate.

Last year, a handful of companies marked the month — which includes World Diabetes Day (Nov. 14) — in a series of ways. Here’s how they’re doing it this year.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

Analysts see multi-year transition to growth for Embecta

Embecta (Nasdaq:EMBC), the BD diabetes business spinoff, may take a few years to move into a growth phase, analysts say.

BTIG analysts Marie Thibault and Sam Eiber wrote a report labeling Embecta as a “Neutral” option on the market. BD initially announced it would spin off its diabetes business in 2021, finally completing the move in April 2022.

The company’s first quarterly results as a spinoff inspired early confidence, beating the consensus forecast on Wall Street. However, the analysts aren’t jumping at the stock too soon.

“We expect this to be a multi-year transition from a value story to a growth play,” Thibault and Eiber wrote.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

How Embecta is ‘uniquely positioned’ in diabetes space following spinoff from BD

Unlike most “new” companies, Embecta enters the playing field with nearly a century of history in diabetes.

Nearly one year after BD (NYSE:BDX) announced its intent to spinoff its diabetes business, Embecta (Nasdaq:EMBC) now stands on its own.

On April 1, the spinoff was made official, and Embecta became a standalone, publicly-traded company aiming to make waves in the diabetes industry. However, unlike most companies just entering the space, Embecta comes in with a wealth of experience, according to former Worldwide President of BD Diabetes Care and new Embecta CEO Devdatt Kurdikar, who spoke with Drug Delivery Business News following the spinoff’s completion on April 1.

“Our mission is to develop and provide solutions for people with diabetes, Kurdikar said. “While we might be a newly listed company today, we have a 98-year history of being in this business. Insulin itself has been used to treat diabetes since 1922, and just two years after that, we i…

Read more
  • 0

How Embecta is ‘uniquely positioned’ in diabetes space following spinoff from BD

Unlike most “new” companies, Embecta enters the playing field with nearly a century of history in diabetes.

Nearly one year after BD (NYSE:BDX) announced its intent to spinoff its diabetes business, Embecta (Nasdaq:EMBC) now stands on its own.

On April 1, the spinoff was made official and Embecta became a standalone, publicly-traded company aiming to make waves in the diabetes industry. However, unlike most companies just entering the space, Embecta comes in with a wealth of experience, according to former Worldwide President of BD Diabetes Care and new Embecta CEO Devdatt Kurdikar, who spoke with Drug Delivery Business News following the spinoff’s completion on April 1.

“Our mission is to develop and provide solutions for people with diabetes, Kurdikar said. “While we might be a newly listed company today, we have a 98-year history of being in this business. Insulin itself has been used to treat diabetes since 1922 and, just two years after that, we in…

Read more
  • 0

BD completes spinoff of Embecta diabetes company

BD (NYSE:BDX) announced today that the planned spinoff of its diabetes business — named Embecta (Nasdaq:EMBC)— has been made official.

Franklin Lakes, New Jersey-based BD announced its intention to spinoff the diabetes business in May 2021, then unveiled the soon-to-be independent, publicly-traded company during the first half of 2022 as “Embecta” in December 2021. BD said the separation of the diabetes business from the rest of the company is consistent with its growth strategy and enhances the ability of Embecta to attract capital investment, recruit talent and allocate resources.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

BD provides Embecta spinoff update, plans for April 1 completion

BD (NYSE:BDX) announced today that it still expects the spinoff of its diabetes business — named Embecta — to complete on April 1.

Franklin Lakes, N.J.-based BD announced in May 2021 that it intended to spin off its diabetes care business as an independent, publicly-traded company during the first half of 2022, and in December 2021, it unveiled the name of the new business as “Embecta.”

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

BD board approves embecta diabetes business spinoff

BD (NYSE:BDX) announced today that its board of directors approved the planed spinoff of its diabetes care business, embecta.

Franklin Lakes, N.J.-based BD confirmed in May 2021 that it planned to spin off its diabetes care business as an independent, publicly-traded company during the first half of 2022 and in December 2021 it confirmed the naming of the new business as “embecta” (Embecta Corp.).

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0